Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Prelude Therapeutics Inc
PRLDCurrent price
0.74 USD
-0.0082 USD (-1.09%)
Last closed
0.71 USD
Company
www.preludetx.com
ISIN
US74065P1012
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
49 295 028 USD
Yield for 12 month
-84.29 %
1Y
3Y
5Y
10Y
15Y
PRLD
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. Address: 175 Innovation Boulevard, Wilmington, DE, United States, 19805
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
+3 000 000 USD
Last Quarter
–
Current Year
-1 169 000 USD
Last Year
-3 042 000 USD
Current Quarter
+3 000 000 USD
Last Quarter
-452 000 USD
Key Figures PRLD
1 year
3 years
5 years
10 years
EBITDA
-141 648 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-39.29 %
PEG Ratio
–
Return On Equity TTM
-66.64 %
Wall Street Target Price
5.00 USD
Revenue TTM
3 000 000 USD
Book Value
2.84 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.77 USD
Diluted Eps TTM
-1.77 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PRLD
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PRLD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Stock Valuation PRLD
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
14.68
Enterprise Value EBITDA
-0.54
Price Book MRQ
0.28
Financials PRLD
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PRLD
For 52 weeks
0.80 USD
6.80 USD
50 Day MA
1.33 USD
Shares Short Prior Month
2 896 842
200 Day MA
3.58 USD
Short Ratio
7.51
Shares Short
3 056 648
Short Percent
17.63 %
BeatStart